electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in...
electroCore Announces Second Quarter 2024 Financial Results
August 07, 2024 16:01 ET
|
electroCore, Inc.
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ...
electroCore to Join Russell Microcap® Index
June 11, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the...
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
June 06, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced...
Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle Biopharmaceuticals, Clexio Biosciences
April 29, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 29, 2024 (GLOBE NEWSWIRE) -- Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle...
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 16:05 ET
|
electroCore, Inc.
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY,...
electroCore to Participate in Upcoming Investor Conferences
March 12, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy...
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
March 05, 2024 16:05 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
November 15, 2023 08:15 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical...
electroCore Announces Third Quarter 2023 Financial Results
November 08, 2023 16:01 ET
|
electroCore, Inc.
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5...